What's Happening?
The African Development Bank (AfDB) has finalized a $15 million loan to Biovac, a Cape Town-based vaccine manufacturer, to support the establishment of a multi-vaccine manufacturing facility. This initiative is part of a broader expansion plan to increase
Biovac's annual manufacturing capacity to 500 million doses. The facility will focus on producing oral cholera vaccines and inactivated polio vaccines, marking a significant step towards Africa's health sovereignty. The project aligns with the African Union's goal to produce 60% of the continent's vaccines locally by 2040, reducing reliance on imported doses.
Why It's Important?
This investment is crucial for Africa's health sovereignty, aiming to transform the continent from a consumer to a producer of vaccines. It addresses the high dependency on imported vaccines, despite Africa bearing a significant burden of vaccine-preventable diseases. The project is expected to create jobs and enhance skills in vaccine manufacturing, contributing to economic growth and stability. It also aligns with global health initiatives, potentially increasing Africa's share in UNICEF and Gavi vaccine tenders, thereby strengthening regional value chains.
What's Next?
The facility is expected to be completed by 2028, with initial production focusing on oral cholera vaccines, followed by inactivated polio, pneumococcal, and meningitis vaccines. The project will connect with Africa's emerging vaccine-financing architecture, including Gavi's African Vaccine Manufacturing Accelerator. The next phase will involve monitoring the facility's progress, achieving WHO prequalification milestones, and increasing the market share of African-made vaccines in global tenders.
